Skip to main content
Thursday, August 27, 2026
BTC $80,228 ▼ 0.05%
GOKHSHTEIN.
Live WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
More SectionsDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
LIVE
ADA$0.214down−0.10%ETH$2,510down−0.10%LINK$11.89down−0.23%SOL$108.98down−0.16%BTC$80,228down−0.05%XRP$1.45down−0.07%S&P 5007,731up+0.72%Nasdaq26,541up+1.57%Dow53,569up+0.20%RUT3,014up+0.28%TNX4.67%up+0.17%TYX5.19%up+0.10%FVX4.40%up+0.34%IRX3.68%down−0.33%VIX14.51down−4.60%GOLD$4,648.50down−0.33%SILVER$69.98down−0.37%OIL$83.51down−0.02%DXY99.11down−0.05%NVDA$227.98up+8.74%AAPL$314.58up+0.36%TSLA$354.81up+2.60%META$571.10down−0.87%MSFT$505.06up+1.75%AMZN$256.26down−1.54%GOOGL$340.65down−0.39%Fear & Greed73 — GreedADA$0.214down−0.10%ETH$2,510down−0.10%LINK$11.89down−0.23%SOL$108.98down−0.16%BTC$80,228down−0.05%XRP$1.45down−0.07%S&P 5007,731up+0.72%Nasdaq26,541up+1.57%Dow53,569up+0.20%RUT3,014up+0.28%TNX4.67%up+0.17%TYX5.19%up+0.10%FVX4.40%up+0.34%IRX3.68%down−0.33%VIX14.51down−4.60%GOLD$4,648.50down−0.33%SILVER$69.98down−0.37%OIL$83.51down−0.02%DXY99.11down−0.05%NVDA$227.98up+8.74%AAPL$314.58up+0.36%TSLA$354.81up+2.60%META$571.10down−0.87%MSFT$505.06up+1.75%AMZN$256.26down−1.54%GOOGL$340.65down−0.39%Fear & Greed73 — Greed
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarketsGo PRO
Company
AboutContactThe NetworkEditorial StandardsCorrectionsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

cancer treatment

1 article

Revolution Medicines' Rasonque Doubles Pancreatic Cancer Survival
Research & Analysis2h ago
Revolution Medicines' Rasonque Doubles Pancreatic Cancer Survival
Approval of the once-daily pill, which extended median survival from 6.7 months to 13 months in late-stage trials, values the company at $46 billion as it targets a previously untreatable protein mutation.